High-Dose Toremifene as a Promising Candidate Therapy for Hormone Receptor-Positive Metastatic Breast Cancer with Secondary Resistance to Aromatase Inhibitors

There are currently no established second- and later-line therapies for postmenopausal women with hormone receptor-positive advanced or metastatic breast cancer. We examined the efficacy of high-dose toremifene (HD-TOR) for this patient group and whether aromatase inhibitor (AI) resistance influence...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Int J Breast Cancer
Главные авторы: Fushimi, Atsushi, Tabei, Isao, Fuke, Azusa, Okamoto, Tomoyoshi, Takeyama, Hiroshi
Формат: Artigo
Язык:Inglês
Опубликовано: Hindawi 2020
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7037483/
https://ncbi.nlm.nih.gov/pubmed/32099680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2020/7156574
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы